AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
19.3.2024 09:00:00 EET | Business Wire | Press release
Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024. The diversity of Galderma’s portfolio, designed to meet the individual needs of healthcare professionals and patients, will be showcased in 16 research posters – including data from the world’s most diverse range of fillers (Restylane®), leading neuromodulator portfolio (RelabotulinumtoxinA, Alluzience® and Azzalure®) and original biostimulator (Sculptra®) – as well as two symposia and a booth, which will host an array of live demonstrations and ‘Meet the Expert’ sessions.
|
“Galderma’s extensive activities at AMWC demonstrate our commitment to pushing the boundaries of injectable aesthetics, to anticipate and address tomorrow’s needs today. By evolving and expanding our existing treatments, developing new innovations, and conducting cutting-edge research into the groundbreaking trends that are anticipated to drive the future of aesthetics, our future-facing approach ensures we continue to deliver the best for healthcare professionals and patients.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
Educating on the future of aesthetics and Sculptra’s expanding indications
The Galderma-sponsored symposium, The AART ™ and Science behind NEXT, will host a panel of world-renowned aesthetic experts, including Dr. Sebastian Cotofana, Dr. Alessandra Haddad, Dr. Christoph Martschin, Dr. Andreas Nikolis, Dr. Sachin Shridharani, and Dr. Van Park, who will delve into the six identified groundbreaking trends that are anticipated to drive the future of aesthetics and how they will impact consultation and interaction with patients. A live demonstration will show how to best integrate the trends’ insights in practice via Galderma’s holistic assessment tool, the AART methodology, and create bespoke treatment plans for patients. The event is taking place in Room Prince Pierre on Wednesday March 27, 2024, from 2:00 to 4:00 PM CET.
As we celebrate 25 years of science and expertise in biostimulation with Sculptra, Galderma’s second symposium, The AART™ of Sculptra beyond the face, will focus on how to use the AART assessment tool to address patients’ body concerns and needs. Prominent experts in the field, including Dr. Luiz Avelar, Dr. Sebastian Cotofana, Dr. Alessandra Haddad, and Dr. Marcus Morais, will focus on how to assess and treat the gluteal (buttock) region to address different patient profiles with Sculptra treatment. Through clinical cases, they will also touch on Sculptra’s use on the décolletage, neck and upper arms. The event is taking place in Room Van Dongen on Thursday March 28, 2024, from 11:00 to 11:55 AM CET.
Extensive data spotlight how Galderma is advancing dermatology for every skin story
Pivotal clinical data supporting the safe and effective use of Restylane SHAYPE™ for augmentation and correction of chin retrusion, with clinical results sustained for up to 12 months, will be presented.1 Restylane SHAYPE is the latest innovation in hyaluronic acid (HA) injectables, powered by new NASHA HD™ technology, the next generation in HA science. Restylane SHAYPE is engineered to shape angles in the lower face by providing a bone mimicking effect.1 It is the newest addition to the Restylane portfolio, the world’s most diverse range of fillers with over 27 years of clinical data, which encompasses different technologies (NASHA®, OBT™ and now NASHA HD) and gel characteristics, with solutions available to meet the needs of patients and injectors all over the world.4 Additional data from studies of Restylane VOLYME™ and EYELIGHT™ will be shared for midface augmentation and correction of infraorbital hollows (dark under-eye shadows and grooves), respectively, with improvements maintained through to 12 months.5,6
New data from the phase III READY-1 and READY-2 studies will also be presented, showing high patient-reported satisfaction and improved wellbeing through six months after treatment with RelabotulinumtoxinA for glabellar lines (frown lines) and lateral canthal lines (crow’s feet).2,3 The treatment was well tolerated and improvement in frown line and crow’s feet severity and aesthetic appearance was maintained through six months.2,3 Developed using Galderma’s proprietary PEARLTM technology, RelabotulinumtoxinA is a highly-active, ready-to-use solution that delivers fast and sustained results and maximizes ease-of-use to address the real needs of patients and healthcare professionals.7-19
Six posters on Sculptra, the first and original biostimulator, with a unique PLLA-SCA™ formulation that activates the body's natural power to revitalize key components of the skin for a more youthful appearance, will be presented at AMWC. Additional data spanning our leading neuromodulator portfolio, Alluzience and Azzalure, will be presented, as well as a new skin quality assessment scale and the AART-HIT™ approach for combining aesthetic products to maximize patient outcomes.
More details on scientific presentations supported by Galderma at AMWC can be found here.*
|
*All presenters are paid consultants or employees of Galderma. |
About the Restylane® Portfolio
With more than 27 years of experience, over 160 clinical publications, and trusted with 65 million treatments and growing worldwide, the Restylane portfolio’s three complementary gel technologies – NASHA®, OBT™ and NASHA HD™ – allow for individualized, natural-looking results and long-term patient satisfaction.4,20,21 The uniqueness and complementary nature of the Restylane portfolio allows for individualized, natural-looking results, providing long-lasting improvement and long-term satisfaction for patients’ self-confidence.4,20-23
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid neuromodulator with a proprietary strain and manufactured using a unique state-of-the-art process. It is designed as a liquid, avoiding the traditional requirement to reconstitute from powder and eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally by Galderma, to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA is an investigational product and has not received approval for any indication in any country.
About Sculptra®
Sculptra is the original biostimulator and is clinically proven to stimulate the skin's innate collagen (type I) production to increase skin firmness and radiance, for long-lasting, natural-looking rejuvenated appearance. Sculptra is proven to increase collagen type I by 66.5% after three months through a process that starts stimulation as early as five days after injection.24 It helps progressively restore the skin’s foundation and natural structural function. Sculptra is proven to achieve natural-looking results that last for more than two years.25 Sculptra provides targeted collagen stimulation, with unique treatment protocols developed for each treatment area and to achieve the patients’ desired results.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
|
References |
|
1. Nikolis, A, et al. Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HASHA, for Augmentation and Correction of Chin Retrusion. E-poster presented at AMWC 2024 |
|
2. Gold, M, et al. Subject-Reported Improvement in Well-Being and High Satisfaction After Glabellar Line Treatment with RelabotulinumtoxinA, an Investigational ready-to-Use Liquid Botulinum Toxin (READY-1 Phase III Trial). E-poster presented at AMWC 2024 |
|
3. Grunebaum, L, et al. Improved Well-Being and Natural-Looking Results After Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin (READY-2 Phase III Trial). E-poster presented at AMWC 2024 |
|
4. Carlo Di Gregorio. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC 2024 |
|
5. Ren, R, et al. Midface Augmentation in Chinese Subjects Using a Flexible Hyaluronic Acid Filler Evaluated in a Randomized No-treatment Controlled Study. E-poster presented at AMWC 2024 |
|
6. Biesman, B, et al. A Study Evaluating the Safety and Effectiveness of Hyaluronic Acid Filler HAEYE for Correction of Infraorbital Hollows (IOH, Tear Trough Study). E-poster presented at AMWC 2024 |
|
7. Galderma. Data on file. Clinical Study Report for Protocol 43QM1602: READY-1. Galderma Laboratories; 2021 |
|
8. Galderma. Data on file. Clinical Study Report for Protocol 43QM1901: READY-2. Galderma Laboratories; 2021 |
|
9. Galderma. Data on file. READY-2 Post-hoc Tables. Galderma Laboratories; 2021 |
|
10. Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021 |
|
11. Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021 |
|
12. Galderma. Data on file: Initial results of the phase IIIb 43QM2106 trial; 2023 |
|
13. Galderma. Data on file: Initial results of the phase IIIb 43QM2107 trial; 2023 |
|
14. Solish, N, et al. Treatment of Moderate-to-Severe Glabellar Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-1 Phase III trial. Abstract presented at TOXINS 2024 |
|
15. Ablon, G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024 |
|
16. Bertucci, V, et al. Efficacy and Safety of a Novel Formulation Liquid Botulinum Toxin, RelabotulinumtoxinA, when used for Combination Treatment of Glabellar and Lateral Canthal Lines. Abstract presented at TOXINS 2024 |
|
17. Persson, C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024 |
|
18. Sundberg, AL, and Stahl, U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021 |
|
19. Do, M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022 |
|
20. Nikolis, A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12. |
|
21. Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021 |
|
22. Narins, RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650 |
|
23. Talarico, S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369 |
|
24. Goldberg, D, Guana, A, Volk, A, Daro-Kaftan, E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922 |
|
25. Fabi, S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC 2023 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318297749/en/
Contact information
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom